. 2022 Oct 27;14(21):5292. doi: 10.3390/cancers14215292

Table 3.

Cox proportional hazards regression analysis for recurrence-free survival and overall survival in patients with hepatocellular carcinoma who underwent hepatic resection.

Variable	Univariate Analysis			Multivariate Analysis			Univariate Analysis			Multivariate Analysis
Variable	HR	(95% CI)	p	HR	(95% CI)	p	HR	(95% CI)	p	HR	(95% CI)	p
Age ≥ 70 years (versus < 70 years)	0.99	(0.78–1.25)	0.918	0.95	(0.71–1.25)	0.695	1.18	(0.87–1.60)	0.287	1.09	(0.75–1.56)	0.655
HCV Ab Positive (versus Negative)	1.05	(0.83–1.33)	0.669	0.96	(0.73–1.28)	0.796	1.10	(0.81–1.48)	0.536	0.84	(0.58–1.22)	0.363
Platelets ≥ 15.5 (versus <15.5 × 10⁴/μL)	1.13	(0.90–1.42)	0.295	1.27	(0.92–1.77)	0.146	1.14	(0.85–1.53)	0.364	1.39	(0.92–2.12)	0.122
Albumin ≥ 3.9 (versus <3.9 g/dL)	0.54	(0.43–0.69)	<0.001				0.42	(0.31–0.56)	<0.001
ALT ≥ 29 (versus <29 IU/L)	1.09	(0.87–1.37)	0.461	1.03	(0.79–1.35)	0.806	1.00	(0.74–1.33)	0.973	0.97	(0.69–1.38)	0.884
Prothrombin time ≥ 87 (versus < 87 %)	0.66	(0.53–0.83)	<0.001	0.69	(0.52–0.90)	0.007	0.63	(0.47–0.84)	0.002	0.68	(0.48–0.97)	0.034
AFP ≥ 100 (versus < 100 ng/mL)	1.72	(1.34–2.22)	<0.001				2.16	(1.59–2.94)	<0.001
PIVKA-II ≥ 107 (versus < 107 mAU/mL)	1.68	(1.33–2.12)	<0.001	1.48	(1.12–1.94)	0.005	2.04	(1.51–2.77)	<0.001	1.67	(1.16–2.42)	0.006
ICGR15 ≥ 14.8 (versus < 14.8%)	1.14	(0.91–1.44)	0.253	0.87	(0.65–1.17)	0.361	1.40	(1.04–1.88)	0.025	1.16	(0.80–1.69)	0.430
ALBI score Grade 2 (versus 1)	1.88	(1.49–2.37)	<0.001				2.61	(1.92–3.55)	<0.001
ALBI score Grade 3 (versus 1)	2.59	(1.14–5.90)	0.023				3.24	(1.18–8.94)	0.023
Fib4-index Middle (versus Low)	1.12	(0.67–1.87)	0.675	1.21	(0.68–2.15)	0.524	1.46	(0.70–3.06)	0.317	1.55	(0.68–3.50)	0.296
Fib4-index High (versus Low)	1.35	(0.82–2.22)	0.235	1.58	(0.84–2.98)	0.154	1.86	(0.91–3.81)	0.089	2.42	(0.99–5.93)	0.053
Fibrosis stage f4 (versus f0 or 1 or 2 or 3)	1.12	(0.88–1.43)	0.358	1.19	(0.85–1.65)	0.309	1.00	(0.73–1.38)	0.977	1.12	(0.73–1.72)	0.601
Degree of differentiation Poor (versus Well or Mode)	0.89	(0.48–1.68)	0.730	0.93	(0.46–1.85)	0.826	0.80	(0.35–1.81)	0.590	0.63	(0.25–1.54)	0.309
Tumor size ≥3.0 (versus <3.0 cm)	1.38	(1.09–1.75)	0.008	1.21	(0.90–1.62)	0.216	1.44	(1.05–1.97)	0.022	1.04	(0.71–1.53)	0.847
Number of tumors ≥ 2 (versus 1)	1.90	(1.48–2.44)	<0.001	1.66	(1.24–2.21)	<0.001	1.75	(1.28–2.39)	<0.001	1.46	(1.01–2.11)	0.047
Portal vein invasion Positive (versus Negative)	1.42	(1.11–1.81)	0.006	1.21	(0.91–1.61)	0.193	1.77	(1.26–2.48)	0.001	1.52	(1.01–2.28)	0.043
mALBI 2b or 3 (versus 1 or 2a)	1.77	(1.36–2.31)	<0.001				2.20	(1.60–3.02)	<0.001
Surgical procedure Sectionectomy or more than hemihepatectomy (versus non-anatomic or segmentectomy)	1.32	(1.05–1.67)	0.016	0.96	(0.72–1.28)	0.800	1.50	(1.12–2.02)	0.007	1.33	(0.91–1.93)	0.136
Operative blood loss ≥ 617 (versus <617 mL)	1.35	(1.08–1.70)	0.009	1.19	(0.91–1.55)	0.195	1.51	(1.12–2.03)	0.007	1.16	(0.82–1.64)	0.398
mALF 1 point (versus 0 points)	1.55	(1.21–1.98)	<0.001	1.35	(1.02–1.78)	0.036	2.09	(1.53–2.86)	<0.001	1.95	(1.36–2.80)	<0.001
mALF 2 points (versus 0 points)	3.45	(2.30–5.19)	<0.001	3.02	(1.83–4.98)	<0.001	4.45	(2.76–7.18)	<0.001	3.67	(2.03–6.63)	<0.001

HR; hazard ratio; CI; confidence interval; HCV Ab: hepatitis C virus antibody; ALT: alanine aminotransferase; AFP: alpha-fetoprotein; PIVKA-II: protein induced by vitamin K absence or antagonist-II; ICGR15: indocyanine green retention rate at 15 min; ALBI: integration of albumin-bilirubin; mALBI: modified integration of albumin-bilirubin; mALF: modified albumin-bilirubin grade and α-fetoprotein.